Table 1.
Cell Source | Disease | Type of Study | Reference |
---|---|---|---|
Human embryonic stem cells | Diabetes mellitus | In Vivo | Kroon et al. [42] |
Human adipose tissue-derived mesenchymal stem cells | Type 1 diabetes mellitus | Clinical trial | Trivedi et al. [43] |
Mouse adipose tissue-derived stem cells | Type 2 diabetes mellitus | In Vivo | Wang et al. [44] |
Hematopoietic stem cell transplantation | Chronic myeloid leukemia | Clinical trial | Hackanson and Waller et al. [45] |
Bone marrow-derived mesenchymal stem cells | Liver failure | In Vivo | Kuo et al. [46] |
Human embryonic stem cells | Pulmonary fibrosis | In Vivo | Banerjee et al. [47] |
Autologous hematopoietic stem cells | Refractory Crohn’s disease | Clinical trial | Cassinotti et al. [48] Oyama et al. [49] |
Autologous non-myeloablative hemopoietic stem cells | Multiple sclerosis | Clinical trial | Burt et al. [50] |
Mouse embryonic stem cells | Parkinson disease | In Vivo | Björklund et al. [51] |
Rat autologous adipose tissue-derived stem cells | Wound healing | In Vivo | Zhou et al. [52] |
Allogenic adipose tissue-derived mesenchymal stem cells | Acute ischemic stroke | Clinical trial | De Celis-Ruiz et al. [53] |
Human adipose-derived mesenchymal stem cells exosomes | Atherosclerosis | In Vitro and in vivo | Yu et al. [54] Xing et al. [55] |